and CRF12. Please refer to SOP09 for Adverse Event reporting and to SOP08 for Active TB reporting.

5.1. Reasons for stopping the study medication

5.1.1 Study participant completed therapy means participant completed therapy (i.e. took 60 daily doses for the 2-month high dose regimens and 120 daily doses within 144 days for the standard regimen)

5.1.2 Study medication stopped due to an adverse event : this answer is chosen if study medication has been permanently stopped due to an adverse event. If study medication has been held temporarily due to a

5.1.7 Pregnancy : If study participant became pregnant during the treatment, HCG blood test must be done to document pregnancy and Adverse event initial report (CRF-9) should

5.2.3. If a study participant does not attend a SCHEDULED visit for the end of treatment (i.e. they were scheduled for a visit at 16 weeks for 4RIF and did